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A QUM partnership approach to regulating biosimilars in Australia 
 
The realisation of the potential implications from biosimilars is relatively recent.  The MeSH 
term “biosimilar pharmaceuticals” was only introduced in 2012 and the first PubMed indexed 
journal article on biosimilar was published in August 2004.  The first biosimilar OmnitropeTM 
(somatropin by Novartis/ Sandoz) was approved by European Medicines Agency in April 
20061.  Since then, the European Medicines Agency has approved 18 biosimilars for the 
European Union countries: 5 epoetins, 7 filgrastims, 2 infliximabs, 3 somatrophins, and 1 
follitropin.[2]  Notwithstanding the fact that Australia is a relatively small market when 
compared to the USA or Europe, to date there are 5 biosimilar epoetins (epoetin alfa, 
EprexTM, Jassen-Cilag; epoetin beta, NeoRecormonTM, Roche; epoetin lamda, NovicritTM, 
Novartis; darbepoetin alfa, AranespTM, Amgen; methoxy polyethylene glycol-epoetin beta, 
MiceraTM, Roche), 7 somatrophins (GenotropinTM, Pfizer; HumatropeTM, Eli Lilly; 
NorditropinTM, Novo Nordisk; NutropinTM, Ipsen; OmnitropeTM, Sandoz; SaizenTM, Merck; 
ZomactonTM, Ferring) and 2 follitropins (follitropin alfa, Gonal-fTM, Merck; follitropin beta, 
PuregonTM, Merck) registered on the Pharmaceutical Benefits Schedule in Australia.  There 
are no biosimilars for infliximab or filgrastim on the Australia market as of yet. 
 
Despite the newness of marketing biosimilars, the European Medicines Agency has led the 
global charge in preparing for the ‘onslaught’ of complications that may potentially arise with 
their introduction.  Much has already been written about raising the awareness of the 
differences between biosimilars and originating/ reference listed (innovator) pharmaceuticals 
– this is summarised briefly below.  Commentators have also argued for an alternative 
regulatory pathway for biosimilars and, indeed, some countries have introduced such 
regulatory pathways biosimilars.  The purpose of this presentation is to explore Australia’s 
readiness for biosimilars.  We conclude that policy makers are aware of the potential 
problems associated with the introduction and wider adoption of biosimilars, but the policy 
responses need a congruent approach.  In addition, the existing National Medicines Policy 
could provide the necessary framework and function for the regulation of biosimilars both 
nationally and internationally.  It is not the intention of this article to endorse or reject the 
merits of biosimilars. 
 
                                                          
1 The first recombinant human interferon beta-1b was launched in China in 1989 1. Generics and 
Biosimilars Initiative, Hurdles to Biosimilars in Asia. Generics and Biosimilars Initiative, 2010. 
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This article will first outline the need for a different vocabulary for large molecule weight 
biological pharmaceuticals (biosimilars) as compared to small molecule weight 
pharmaceuticals (generic drugs), followed by issues which need to be addressed by 
policymakers in the sequential steps of regulating biosimilars. 
 
Biosimilars, also otherwise known as “follow-on biologic products”, “follow-on 
biopharmaceuticals”, “follow-on protein products”, “subsequently entered biologics”, 
“similar biologic medicinal products”, “biotech proteins”, and “biopharmaceuticals”; are 
relatively large, three-dimensional molecules.  A biosimilar, like its innovator, is generally 
produced through normal biological processes in living tissues such as Chinese hamster ovary 
cell lines or microorganisms transfected with relevant human genetic material (biotechnology 
and genetic engineering).  By comparison, the majority of the pharmaceuticals on the market 
until recently are small molecule pharmaceuticals, which are often produced through ex vivo 
chemical synthetic processes.  The brand versions of these small molecule pharmaceuticals 
are commonly termed as “generic drugs”.   
 
Much interest has been shown in generics because of their potential for cost savings.[3]  For a 
generic pharmaceutical manufacturer to have its pharmaceutical approved, an applicant 
typically only has to prove through pharmacokinetic studies that the active ingredient has an 
equivalent rate and extent of absorption within a 90% confidence interval of the innovator, 
branded, pharmaceutical (bioequivalence).  It is, therefore, assumed that similar products 
with similar pharmacokinetic profiles will have very similar clinical effects; hence there is no 
need for complex clinical trials to demonstrate the generic’s safety and efficacy.  Regulators 
are generally comfortable to extrapolate clinical indications for use from the innovator to the 
generic, and, indeed, generic drugs must retain the same indications as those of the innovator 
drug product upon which their development is based, without the need to conduct expensive 
human trials to demonstrate safety and efficacy.  A generic manufacturer can therefore 
market its products at a lower price than the innovator.  Many generic manufacturers are also 
able to free-ride/ rely on the marketing, reputation, experience and expanded indications of 
use secured by the innovator’s manufacturers.  Consequently, because of the lower cost, 
many health economists postulate that increased use of generics will result in cost savings to 
the public funder and health insurer.  In the USA, more than 70% if all drugs sold, by 
volume, are now generics.  The counter-measure often mounted by the innovator 
manufacturer is to seek longer and broader intellectual property protection to maximise its 
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return on investment and hence reward its innovation.  Many innovator manufacturers are 
ready, willing and able to instigate legal actions against potential generic manufacturers as a 
means of stalling the entry of generic versions of their small molecule pharmaceuticals.[4, 5]  
The debate as to whether an innovator deserves longer and broader intellectual property 
protection had been discussed elsewhere [6] and is not the focus of this article. 
 
Many scholars have warned of the dangers of treating biosimilars like small molecule 
generics.  Specifically, biosimilars are larger in size, more complex in structure, and contain 
greater heterogeneity than a generic drug.  These differences have a profound influence on 
biosimilars' biological functions and clinical properties.  To illustrate, aspirin weighs 180 
Daltons while the biosimilar version of recombinant human erythropoietin hormone 
darepoetin alfa weighs 37,100 Daltons.  Aspirin contains only 21 atoms; darepoetin alfa is 
comprised of 165 amino acids.  Each amino acid contains between 13 to 26 atoms.  The 
amino acid components of darepoetin alfa constitute 60% of its molecular weight with the 
remaining comprising of carbohydrate complexes.  Furthermore, darepoetin alfa is also 
different from its innovator (epoetin) by weighing 6,700 Daltons more, contains two extra N-
linked oligosaccharide chains and an extra carbohydrate composition of 11%.  These 
differences result in a longer half-life, increased biological activity and decreased receptor 
affinity.[7]  Nonetheless, darepoetin alfa reportedly has a safety profile similar to its 
biosimilar epoetin alfa competitors.[7-9] 
 
The implications of a biosimilar being a larger molecule than generic drug are such that all 
steps of production and purification can influence the clinical properties of the final 
product.[10-21]  Inter- and intra-batch variations in biological manufacturing are expected.  
Extensive analytical, preclinical and clinical data are required to ensure that a large molecule 
pharmaceutical is indeed biologically similar to the reference innovator drug, and also 
between batches.  Whilst chemically synthesised small molecule pharmaceuticals up to 1,000 
Daltons can be reproducibly manufactured within one-hundredth Daltons across batches.  
Large molecular weight biological pharmaceuticals may vary by 1,000 Daltons due to the 
heterogeneity of the production process.[16]  The quality and safety standards for biosimilars 
to ensure inter- and intra-batch consistency are much higher in comparison to generic drugs.  
Furthermore, the complexity of a three-dimensional biological product meant that even if the 
molecular weight of the biosimilar is identical to that of the reference innovator product, the 
actual configuration/ shape of the biosimilars may nonetheless has considerable variations 
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inter- and intra-batch, as well as differences to the innovator product.  Such clinical safety 
and efficacy issues are paramount.  The analytical methods currently available often cannot 
characterise such complex biological pharmaceuticals sufficiently to confirm structural 
equivalence of a biosimilar with its reference innovator product.[11, 22, 23]  The particular 
issues of immunogenicity, efficacy and safety with biosimilars are discussed below. 
 
Consequently, most experts agree that the term “biogeneric” would create the false 
impression that a biosimilar pharmaceutical is identical to its innovator product, similar to the 
situation for small molecule generic drugs. 
 
There are high hopes that biosimilars will be able to develop the same magnitude of cost 
savings to the public and private health insurers as have the small molecule generics.[23]  
The projected sales of biosimilars by 2015 is expected to be US$1.9 – 2.6 billion 
globally.[24]  This currently represents only 16% of the total global pharmaceutical 
expenditure.[24] However, a major change will occur when the current 12 highest volume 
biological pharmaceuticals worth US$67 billion in global sales come off patent on or about 
2020.[25, 26]  It is anticipated that then the biosimilars market has the potential to be the 
single fastest-growing pharmaceutical sector.[24]  This has already stimulated the emergence 
of non-conventional pharmaceutical investors such as Brazil, China, India, Mexico, Russia, 
South Korea and Turkey, which view biosimilars as a key macroeconomic driver of 
growth.[1, 27-33] 
 
Economic imperatives have conventionally been used as the justification for wider 
intellectual property protection as a means to incentivize innovation.[6]  Intellectual property 
is the subject of international collaboration due to the global nature of trade and commerce.  
There are many facets to the issue of intellectual property protection, which are of relevance 
to the regulation of biosimilars in Australia.  The issue of patents is discussed below.  
 
As acknowledged by IP Australia, the aim of the Australian patent system is primarily 
economic:[34] an exchange of exclusive rights in returns for innovation.[6]  The critical issue 
with biosimilars and the Australian patent system is whether the current system impedes the 
entry of biosimilars into the marketplace. 
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The cost of pharmaceutical research and development is expensive: approximately US$802 
million per new compound, when taking into account both failures and successes for any one 
firm.[35]  The estimate for bringing a biological pharmaceutical to market is US$1.2 billion, 
again, taking into account failures as well as successes for any one firm.[36]  Consequently, 
to maximise one’s return on investment, it is a common practice for the innovator 
manufacturer to seek patent protection for both upstream production and downstream 
innovation.[37, 38]  The requirements for a patent applicant to provide full disclosure of 
inventions claimed during the patent application process has resulted in the common practice 
for the applicant to cover a broader field by construing overly broad claims to include 
families of chemical compounds with common features.[39]  Furthermore, some innovators 
have adopted a stepwise improvement of their products to “evergreen” them, creating a patent 
thicket to hamper the entry of generics.[34, 40-43]  As patent rights are chose in action and 
critical to business viability, innovator companies are ready, willing and able to enforce their 
legal rights; utilising the legal system to challenge and for some, to delay, entry of 
generics.[5, 44, 45]  
 
IP Australia recently completed a review of Australia’s pharmaceutical patent system.  The 
panel of experts acknowledged in the draft report that ‘biosimilars are not considered to be 
bioequivalent to a reference biological product. This is due to the highly complex nature of 
biological medicinal products’ [46](p.189);  ‘The clinical performance of biologics is often 
highly dependent on the methods of manufacturing and purification.  Even minor differences 
in the environment or manufacturing process can compromise biological activity and safety, 
for some biologic drugs.’ (p.193, references omitted).  Nonetheless, the Panel held that ‘the 
patent landscape for biologics is no more complex than that for small molecule drugs’ (p.192) 
and did not warrant specific patent protection such as increased length of confidential data 
protection or extended patent terms.  
 
For biosimilars, the upstream process and methods of manufacturing are more critical than 
that for small molecule pharmaceuticals with respect to safety and efficacy[15].  For 
example, when the biosimilar to epoetin alfa, Eprex™ was blamed for increased 
immunogenicity and development of pure red cell aplasia, two hypothetical causes were 
offered: (i) leachates from uncoated rubber stoppers, and (ii) the change from human serum 
albumin to polysorbate 80 as a stabiliser.[10, 16, 19, 47, 48]  The differences in upstream 
production of biosimilar can result in significant difference in the biological characteristics of 
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the downstream product.[49, 50]  The upstream-downstream nexus is more relevant for 
biosimilars than for small molecule generics.  Each biosimilar manufacturer can, and does, 
use his or her own specific cell lines, applied unique fermentation and purification process, 
and contain different composition of inactive ingredients in the product’s downstream 
formulation.[23] 
 
If the principal objective of the patent system is to incentivize innovation one must rightly 
question whether the consequence of a biosimilar manufacturer attempting to patent and 
protect various modes of upstream manufacturing as well as the downstream product itself 
does, in fact, stimulate innovation.   
 
Australia recently enacted the Intellectual Property Laws Amendment (Raising the Bar) Act 
2012 aiming to address the issue of the “patent thicket”.  The amendment came into effect on 
15 April 2013.  Section 7 of the Patent Act 1990 was amended with respect to an element of 
the legal test that decides whether the subject of a patent application is “inventive”, and hence 
be afforded patent protection.  The amended section relates to the common general 
knowledge/ prior art base, which a skilled addressee may consider.  The prior art base is no 
longer restricted to information extant in Australia.  Furthermore, sections 18 and 7A require 
that a patent needs to be of particular benefit to the public as disclosed in its current form, as 
opposed to whether it could prove useful at some future date after further research.  Section 
40(2)(a) demands that the disclosure of the invention be clear enough, complete enough and 
contain the best method known to the patent applicant for the invention to be recreated by a 
person skilled in the relevant art.  The effect of amended section 40(3) imposes on the patent 
applicant the duty to fairly base the description of each of its claims and mandates that the 
scope of the claims not be broader than is justified by the extent of the description.   
 
The Raising the Bar Act may be a double-edged sword for the patentability of biosimilars.  
On the one hand, the amendments may narrow the scope of claims upon which the innovator 
manufacturer can fairly base its invention, thereby narrowing the scope of the patent, and 
making it easier for a biosimilar sponsor to seek a patent for its product.  The amendments 
may also have the effect of preventing evergreening of one’s pharmaceutical product, once 
the patent has been granted.  However, on the other hand, the amendments may make it easier 
for an existing patent holder  to challenge the validity of a later and competing biosimilar 
patent application, since the relevant skilled addressee is no longer restricted to consider the 
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breadth and location of prior art base in assessing “inventiveness”.  This has the effect of 
moving the Australian patent system from registration to litigation. 
 
It was only recently, as a result of the Australia-USA Free Trade Agreement, that the 
standard patent terms have increased to 20 years, plus an additional maximum of five years 
for pharmaceuticals.  This extended term was estimated to cost the Pharmaceutical Benefits 
Scheme ‘$6 million in 2001-02, increasing to $160 million in 2005-06, due to delays in the 
introduction of generic products.’[34](p.5).  The USA has a protectionist policy for 
pharmaceuticals since a majority of the global pharmaceutical manufacturers are based in the 
USA.[6, 51, 52]  It is not surprising that there have been allegations of the USA exerting 
pressure on its trading partners through international trade treaties for longer pharmaceutical 
patent terms.[53-57]  No detail has been provided nor confirmed as to the effect of the current 
Trans Pacific Partnership Agreement on patentability of biosimilars in Australia. 
 
In USA, the Biologics Price Competition and Innovation Act 2009 provided a new process 
for the resolution of patent disputes between the innovator manufacturer and the biosimilar 
patent applicant.[36]  The latter must disclose to the innovator manufacturer detailed 
(confidential) product and manufacturing information at the time of submission of an 
application for licensing of the product (BLA) to the Food and Drug Administration.  The 
innovator manufacturer must then provide to the biosimilar manufacturer a list of patents that 
are potentially infringed.  The parties are expected to work together in good faith to 
determine which patents will be litigated.  
 
IP Australia in its draft report recognised a need for an integrated approach to the regulation 
of pharmaceuticals beyond patent issues.[46]   
 
If the essence of intellectual property is economic, the notion of a liberal free market is of 
utmost important.  The key to the existence and flourishing of a free market is a society in 
which the rights and titles of property are respected, defended and kept secure; whilst free 
from coercion and threat.[58]  With the tendency towards litigation in the USA as a means of 
delaying entry of generic drug products, European Union competition policy and USA 
antitrust law have been invoked to suppress the anti-competitive practices by some innovator 
manufacturers.[59-62]  Similarly, cartel conduct is also prohibited in Australia under Part IV 
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Division 1 of the Competition and Consumer Act 2010.  However, to our knowledge no 
pharmaceutical company has been prosecuted in Australia for anti-competitive behaviour. 
 
For a pharmaceutical product to be supplied in Australia, a sponsor must apply to the 
Therapeutic Goods Administration for its product to be listed in the Australian Register of 
Therapeutic Goods.  During the assessment process, detailed product (e.g., safety and 
efficacy) and manufacturing information have to be submitted to the Therapeutic Goods 
Administration. 
 
 
Confidential information 
 
To evaluate the quality assurance of the manufacturing of biosimilars, knowledge of 
analytical methods, in-house standards, specifics of the production process, historical 
development process, validation and full characterisation data are needed.[12]  However, 
these are deemed proprietary information and little is available in the public domain.  A 
systematic review of research outcomes and pharmaceutical sponsorship found that research 
funded by the pharmaceutical industry was less likely than publicly-funded research to be 
published; and if published, more likely be in favour of the sponsor (OR 4.05, 2.98 – 
5.51).[63]  There have been allegations that pharmaceutical companies have selectively 
published favourable findings and self-funded research, which bolster one’s apparent success.  
Unfavourable findings were not published so as to be afforded copyright protection for 
unpublished works.  The copyright term for published works in Australia is now 70 years 
plus the life of the author.  Copyright terms for unpublished works do not commence until 
publication takes place. 
 
As information about the upstream process and methods of manufacturing are critical to the 
downstream biosimilar product, the availability of confidential information takes on extra 
importance.   
 
In the USA, under its new biosimilars legislation, there is a 12-year marketing exclusivity 
period for the reference biological product (innovator), one year of exclusivity for the first 
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biosimilar product deemed interchangeable with the innovator, and a further six months of 
exclusivity for development of a paediatric indication.[36, 64-68]   
 
The Therapeutic Goods Administration is also bound by specific data exclusivity provisions 
under the Therapeutic Goods Act 1989 (Cth).  Data exclusivity in Australia is currently five 
years pursuant to section 25A of the Act.  Within this time, the Therapeutic Goods 
Administration cannot without the permission of the innovator utilise the initial data 
submitted to assess a subsequent biosimilar application from another sponsor.  The data 
exclusivity provision does not, however, prevent a biosimilar manufacturer from conducting 
its own research and submit its own dossier for listing by the Therapeutic Goods 
Administration within this data protection period.  However, due to the high cost of bringing 
biological pharmaceuticals to market and the difficulty of reverse-engineering such products, 
confidential information about the innovator has more commercial value to the biosimilar 
manufacturer than to a small molecule generic manufacturer. 
 
Currently the Therapeutic Goods Administration is in the process of reviewing its policy on 
disclosure of commercially confidential information under section 61 of the Act, which may 
enable it to share confidential information with other regulators.  This is of relevance to 
biosimilars because of the global nature of pharmaceutical trade, which warrants international 
collaboration in the regulation of safety and efficacy of pharmaceuticals of all types. 
 
It is comparatively easy to reverse-engineer a small molecule pharmaceutical than a 
biological pharmaceutical.  The Australian Government Department of Health and Ageing 
conceded ‘it is unlikely that any second manufacturer attempting to replicate a protein 
product will be able to reproduce precisely the process used by the manufacturer of the 
reference product.  Thus, even though SBMP [biosimilars] will have the same encoding DNA 
sequence as the reference product, the two products may differ in key attributes. This in turn 
has potential implications for the safety and efficacy of the different products.” [69](para 3) 
 
The European Medicines Agency has led the regulation of biosimilars since 2003.  The 
regulatory process has been inclusive of the pharmaceutical industry and the regulator 
through the development of concept papers, followed by draft guidelines.  Clinical, non-
clinical and product class guidelines are publicly available. 
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Consequently, several countries have looked upon European Medicines Agency regulations 
for guidance.  Specifically, the Therapeutic Goods Administration has opted to adopt 
European Medicines Agency guidance in the regulation of biosimilars.  Nonetheless, with the 
globalisation of the pharmaceutical industry, there are at least 18 international guidelines on 
regulation of biosimilars in the following countries:  Argentina, Australia, Brazil, Canada, 
Chinese Taipei (Taiwan), Costa Rica, India, Iran, Japan, Malaysia, Mexico, Saudi Arabia, 
Singapore, South Africa, South Korea, Turkey, the USA, and World Health Organization.[30, 
32, 33, 70-72] 
 
There are, however, sufficient similarities across international regulations.  For instance, 
there is a need for a head-to-head comparison between the biosimilar and the reference 
product (innovator) for analytical properties, safety and efficacy through non-clinical and 
clinical studies, in varying degrees across regions.  The comparative study needs to be of 
equivalence design with established lower and upper comparability margins.  In these studies, 
state of the art technologies are preferred, with at least one repeat-dose toxicology study, with 
use of relevant animal species and of sufficient duration. 
 
However, differences also exist across international regulators.   
 
With regard to the innovator reference product, Japan demanded that the host cell type for the 
biosimilar and the reference product must be the same.  The European Medicines Agency 
required a comparison to be made against the reference product authorised and registered in 
European Union, and a reference product, which is not authorised in European Union 
countries, may only provide supportive information.  The Canadian guideline allows the use 
of a non-Canadian registered product as suitable reference product proxy, but only if the 
proxy is approved in a jurisdiction that has an established relationship with Health Canada, 
has formally adopted the International Conference on Harmonization guidelines, has an 
established regulatory standard, is the subject of post-marketing surveillance activities, and is 
marketed by the same pharmaceutical manufacturer in the same dosage form as the intended 
biosimilar.  The World Health Organization conceded that not all member countries would 
have sufficient resources to meet this standard, hence a biosimilar may still be approved 
where the licensing country lacks an approved reference product.  As alluded to above, a 
biosimilar is not typically identical to the innovator product, hence it is vital to conduct 
comparative studies to ensure that the biosimilar is biologically similar to its reference 
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innovator product.  The differences in international guidelines on how biosimilars are to be 
compared with their innovator reference products has created a gradient of demands which 
biosimilar manufacturers need to meet in bringing their products to their respective markets.  
 
Furthermore, in regard to the analytical process, Japan and the European Medicines Agency 
require direct comparison of process-related impurities as a stand-alone exercise.  Whilst 
Health Canada and the World Health Organization recommended that such an effort should 
be attempted, Japan held that comparisons of product stability are not relevant.  This is 
required in Europe, Canada and by the World Health Organization. 
 
In addition, the definition of a biosimilar in regard to provided clinical data varies.  The 
World Health Organization defined “biosimilar” as “similar treatment at same dosage”.  The 
USA biosimilars legislation demands significant molecular and product similarity, though the 
Food and Drug Administration has not officially defined what “highly similar” or “clinical 
[sic] meaningful differences” mean.  Both Health Canada and the World Health Organization 
held that if the biosimilar product is clinically superior to the reference innovator, it is not 
biosimilar - it could colloquially be considered a “Biobetter.”.  The European Medicines 
Agency asks for clinical comparability to be pre-specified and justified.  The different 
guidelines lead to the potential for a biosimilar, which perform better than its reference 
innovator, to be listed as a biosimilar in some countries and as an innovator product in others. 
 
With the complexity of regulation across jurisdiction, it is important for international 
regulators to share information about biosimilars.  If this occurs, the positive effects would 
include less duplication of documentation required by a biosimilar sponsor in seeking listing 
across jurisdictions; and regulators would be able to focus on particular issues that are of 
utmost important to their own regulatory pathway.  This would reduce the cost of approving 
biosimilars and could translate into actual cost savings to the public funder and health insurer.  
Furthermore, from a public health perspective, information that is not favourable to a 
biosimilar sponsor may become available to other international regulators, should sharing of 
confidential information be available.  This arrangement may be more vital to regulators in 
countries with less stringent regulatory requirements.  In some countries, such as India and 
China, policy makers have consciously lowered the threshold requirement for regulation of 
biosimilars, as other economic imperatives have taken priority.  Consequently there are more 
biosimilars available in China and India than in Europe or the USA.[1]  The sharing of 
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information will enable lower income countries to have access to essential information about 
a particular biosimilar; the higher income countries can learn from the experience and efforts 
of population biosimilar exposure in lower income countries.  
 
With respect to the naming of pharmaceutical products, the International Non-Proprietary 
Name nomenclature conventionally used for small molecule generics may not apply to 
biosimilars in some countries.  The World Health Organization recommended that altered 
amino acid sequences should be denoted by distinct prefixes e.g. darbepoetin and that 
different glycosylation pattern be indicated by Greek letters e.g. alpha, beta.[73]  The 
Japanese Accepted Names Committee established a precise definition of biosimilars that 
include cell substrate, molecular weight, extent of sialylation and nature of N- and O-glycans.  
Biosimilar sponsors in Europe can opt whether or not to choose the International Non-
Proprietary Name.  In Australia, the Therapeutic Goods Administration only in recent months 
dictated that the name of a biosimilar is to be made up of: (i) the reference product’s 
Australian Biologic Name, and (ii) a biosimilar identifier, consisting of: the prefix sim(a)- 
and a three-letter code issued by the World Health Organization’s International Non-
Proprietary Name Committee.  This means that in Australia the biosimilar sponsor will need 
to first apply to the World Health Organization International Non-Propriety Name Committee 
for a biosimilar three-letter code; then to the Australian Biologic Name Committee for the use 
of the International Non-Propriety Name three-letter code in the biosimilar identifier; and 
finally to request for this identifier to be added to the list of Australian Approved Names.  If 
there are detectable quality differences in the biosimilar as compared with the innovator 
product, the biosimilar sponsor will also need a different Australian Biologic Name. 
 
There is a need for standardisation and better collaboration with international regulators if 
entry of biosimilars across regions is to be encouraged. 
 
A key role of the Therapeutic Goods Administration is the assessment of a pharmaceutical 
product’s safety and efficacy.  As alluded to above, even if the molecular weight of the 
biosimilar is identical to its innovator, the biological activity and efficacy may nonetheless 
vary considerably.  Another key factor in safety and efficacy is the immunogenicity of the 
biosimilar and the reference innovator drug.[10, 11, 48, 74-76] 
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Biosimilars are predominately biological protein-based products.  Many biosimilar candidates 
are based on biologicals not found in nature. In other cases, the majority of biological 
pharmaceuticals are not identical to naturally occurring proteins; hence there is a real 
possibility for the human body to recognise the product as foreign, invoke an allergic 
reactions to it, or break immune tolerance.  The process can involve both B and T 
lymphocytes.  This is generally a slow process, which generates a persisting level of 
neutralising antibody to the pharmaceutical, resulting in a loss of activity. Cross reactivity to 
naturally occurring biological substrates can trigger autoimmune phenomena as well. 
 
It is not possible to deduce from the molecular structure of the biosimilar or ascertain with 
certainty from preclinical and animal trials the likelihood of such immunogenicity due to this 
often slow process.  In addition, the antibody response induced by a biosimilar may have a 
different character and clinical consequence as compared to that for the innovator.  A large 
and long duration cohort study may be required to study safety and efficacy of a biosimilar.  
Such a pharmacovigilance study is expensive to conduct due to the duration of the study and 
the number of participants required.  For instance, to study the issue of epoetin alfa-induced 
pure red cell aplasia 30,000 participants would be required and would cost around US$30 
million.[12]  With a biosimilar, post-marketing pharmacovigilance may become the only 
means of conducting such an assessment.  Sharing of information among international 
regulators may be a solution.  With the move to streamline the Therapeutic Goods 
Administration registration and application for Pharmaceutical Benefit Scheme listing 
processes, the sharing of information across agencies will help to avoid the duplication of 
paperwork. 
 
The Pharmaceutical Benefit Scheme is the monopolistic buyer of pharmaceuticals in 
Australia.  In 2011-12, the Scheme subsidised over 4,000 pharmaceutical products and 
represented some 14% of the Australian Government expenditure.[77] 
 
To contain cost the National Health Act 1953 (Cth) was first amended in 2007 to introduce 
F1 and F2 referencing pricing – section 85AB.  Pharmaceuticals listed in the F1 schedule are 
mostly branded innovator products and not interchangeable.  Pharmaceuticals listed in the F2 
schedule are generic.  When an equivalent generic becomes available, the innovator can be 
moved from F1 to F2, resulting in a 16% price reduction.  Section 99ACEA of the Act 
clarified that such a price reduction applies to “same pharmaceutical item”, “same drug” and 
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“biosimilar”.  Regulation 2.14 of the National Health (Pharmaceuticals and Vaccines – Cost 
Recovery) Regulation 2009, which refers to Schedule 1 items 3.1 to 3.2, clarified this as 
“same active ingredient and the same form and manner of administration as an existing 
special pharmaceutical product”.  Collectively, the effect of section 99ACEA enables the 
Australian Government to move innovator biological products from schedule F1 to schedule 
F2 and apply a 16% price reduction when a biosimilar became available on the Schedule.  
However, despite the fact that there are currently 5 epoetins, 7 somatrophins and 2 follitropin 
biosimilars listed in the Pharmaceutical Benefit Scheme, none of the biosimilars and their 
innovators have been moved to F2 pricing. 
 
Many scholars have written about the need for greater awareness of biosimilars.  Most 
prescribers are cautious about utilising biosimilars.[78]  Currently, most biosimilars are 
dispensed through hospital pharmacies.  A question which needs to be answered as 
biosimilars become more common is the appropriateness of the substitution and 
interchangeability of biosimilar. 
 
In recent decades, prescribers are encouraged to prescribe by International Non-Propriety 
Name – a practice inherited from small molecule generic practice.  Prescribing using generic 
names enables the pharmacist to substitute more expensive brand innovator products for 
cheaper generics.  This is often done with the consent of the patient and/or the prescriber.   
 
Currently the Pharmaceutical Benefit Scheme does not allow automatic substitution of 
biosimilars.[69, 79]  This follows similar legislation against automatic substitution in 
California, France, Germany, Netherland, South Africa, Spain, Sweden, and the UK.[23, 30, 
80]  This appears to be congruent with the advocacy for different International Non-
Proprietary Name for biosimilar.  Canada has not addressed this issue, Japan advises health 
practitioners to avoid substitution, while Italy leaves it to the prescriber.[30, 81, 82]  A moot 
point in the USA is whether a biosimilar is “interchangeable” with the reference innovator 
drug, pursuant to section 351(k)(4) of the biosimilar legislation.  If the biosimilar is 
comparable, i.e. “highly similar” or possessed of “no clinically meaningful differences”, it is 
deemed interchangeable with the innovator and the substitution is done automatically without 
prescriber intervention.[30, 83]  The standard of proof for interchangeability is projected to 
be exceedingly high in the USA.  
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As alluded to above, batch-to-batch variation is to be expected with biological 
pharmaceuticals.  When there is only a single brand on the market, any adverse effect such as 
immunogenicity may be tracked to the innovator product, provided that the Australian health 
practitioner does report the adverse effect to Advisory Committee on the Safety of Medicines.  
Not all community pharmacies provide batch tracking.[79]  This poses a logistical issue in 
post-marketing pharmacovigilance of a biosimilar when more than one branded product is 
available on the market.  For instance, looking outside of Australia, there are at least 14 
brands of epoetin, as compared to 5 currently listed in Australia. 
 
 
National Medicines Policy 
 
Considering the issues related to the regulation of biosimilars outlined above, a congruent 
approach is required.  It may not be technically possible to advocate an “integrated” approach 
since the objectives of various existing policies across regions vary in their principles.  
Nonetheless, a congruent approach would enable policy makers in each of the relevant 
domains to consider other stakeholders in biosimilars and a whole of system approach could 
be adopted. 
 
We believe that the National Medicines Policy first adopted by the Australian Government in 
2000 already provided the form and function for a congruent approach to the regulation of 
biosimilar and other advanced pharmaco-technology such as nano-pharmaceuticals and 
pharmacogenetics. 
 
The National Medicines Policy embedded a set of principles within a health system policy 
framework.  It recognised health as a human right whilst at the same time acknowledging that 
improving health has many dimensions and does not exist in isolation.  The Policy concedes 
that pharmaceuticals will be affected by financial policy and trade considerations, 
international treaty obligations, industrial policies, education policies and the need for public-
private partnerships.  The Policy had arguably received bipartisan support as it has survived 
successive governments without change.  The Policy provided a framework, which enables 
regional partnerships and networks to minimise duplication of effort.  This concurs with 
recommendations from IP Australia in its review of the pharmaceutical patents that a body 
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capable of working across sectors is required.  Issues with biosimilars need to be informed 
through conversation within Australia, across sectors, and internationally. 
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